| Characteristics | Frequency | Ratio (%) |
|---|---|---|
| Hospitalization time before CRE infection (days)1) (n=130) | 12 (5–22) | |
| Surgery before determining CRE infection (n=451) | ||
| Yes | 214 | 47.4 |
| No | 237 | 52.6 |
| HAI (n=451) | ||
| Yes | 120 | 26.6 |
| No | 331 | 73.4 |
| Types of HAI (n=120) | ||
| Ventilator-associated pneumonia | 64 | 53.3 |
| Bloodstream infection | 61 | 50.8 |
| Urinary tract infection | 20 | 16.7 |
| Surgical site infection | 15 | 12.5 |
| Invasive procedures (n=451) | ||
| Yes | 438 | 97.1 |
| No | 13 | 2.9 |
| Types of invasive procedures (n=438) | ||
| Urinary catheterization | 399 | 91.1 |
| Central venous catheter | 372 | 84.9 |
| Intubation | 329 | 75.1 |
| Arterial catheter | 255 | 58.2 |
| Exposed to antibiotics (n=451) | ||
| Yes | 418 | 92.7 |
| No | 33 | 7.3 |
| Types of antibiotics (n=418) | ||
| ß-Lactam | 410 | 92.7 |
| Peptides | 207 | 49.5 |
| Quinolons | 195 | 46.7 |
| Oxazolidinones | 103 | 24.6 |
| 5-Nitroimidazoles | 56 | 13.4 |
| Aminoglycoside | 39 | 9.3 |
| Lincosamide | 27 | 6.5 |
| Co-trimoxazole | 16 | 3.8 |
| Macrolide | 5 | 1.2 |
| Tetracyclines | 3 | 0.7 |
| Treatment outcome (n=451) | ||
| Mitigation | 276 | 61.2 |
| Unchangeability | 65 | 14.4 |
| Aggravation | 104 | 23.1 |
| Death | 6 | 1.3 |
| Hospitalization time (days)1) (n=451) | 17 (10–28) | |